Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletion

Experimental Eye Research

Volumn 85, Issue 5, 2007, Pages 617-625

  Chen, Peter W ^a   Mellon, Jessamee K ^a   Mayhew, Elizabeth ^a   Wang, Shixuan ^b   He, Yu Guang ^a   Hogan, Nick ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

immune privilege; immune regulation; tryptophan; tumor escape; uveal melanoma

Indexed keywords

1 METHYL DEXTRO LEVO TRYPTOPHAN; CELL PROTEIN; ENZYME INHIBITOR; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL CULTURE; CELL LINE; CELL LYSATE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UVEA MELANOMA; WESTERN BLOTTING;

ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA, RECOMBINANT; LIVER NEOPLASMS; MELANOMA; METABOLISM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRYPTOPHAN; TUMOR CELLS, CULTURED; UP-REGULATION; UVEAL NEOPLASMS;

EID: 35449004025     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.07.014     Document Type: Article

References (55)

1. Alexander A.M., Crawford M., Bertera S., Rudert W.A., Takikawa O., Robbins P.D., and Trucco M. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51 (2002) 356-365
2. Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12 (2006) 1144-1151
3. Apte R.S., and Niederkorn J.Y. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J. Immunol. 156 (1996) 2667-2673
4. Apte R.S., Mayhew E., and Niederkorn J.Y. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1277-1282
5. Apte R.S., Sinha D., Mayhew E., Wistow G.J., and Niederkorn J.Y. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol. 160 (1998) 5693-5696
6. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A., Ratto G.B., Melioli G., and Frumento G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7 (2005) 390-396
7. Baban B., Chandler P., McCool D., Marshall B., Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61 (2004) 67-77
8. Basu G.D., Tinder T.L., Bradley J.M., Tu T., Hattrup C.L., Pockaj B.A., and Mukherjee P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177 (2006) 2391-2402
9. Bedikian A.Y. Metastatic uveal melanoma therapy: current options. Int. Ophthalmol. Clin. 46 (2006) 151-166
10. Beutelspacher S.C., Pillai R., Watson M.P., Tan P.H., Tsang J., McClure M.O., George A.J., and Larkin D.F. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 36 (2006) 690-700
11. Bodaghi B., Goureau O., Zipeto D., Laurent L., Virelizier J.L., and Michelson S. Role of IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162 (1999) 957-964
12. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., Werner E.R., Werner-Felmayer G., Weiss H.G., Gobel G., Margreiter R., Konigsrainer A., Fuchs D., and Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12 (2006) 1144-1151
13. Chen X., Liu L., Yang P., Wu C., Jin H., Xing L., Li B., Zhou H., Huang X., and Zhu L. Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation. Immunol. Lett. 107 (2006) 140-147
14. Choi B.K., Asai T., Vinay D.S., Kim Y.H., and Kwon B.S. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 34 (2006) 233-242
15. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
16. Cordiali-Fei P., Mottolese M., Tecce R., Natali P., and Ferrone S. Accessory cell function of human melanoma cells in mitogen-induced T cell proliferation. Cell. Immunol. 116 (1988) 149-162
17. Cousins S.W., McCabe M.M., Danielpour D., and Streilein J.W. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 32 (1991) 2201-2211
18. Crispe I.N., Giannandrea M., Klein I., John B., Sampson B., and Wuensch S. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213 (2006) 101-118
19. Daubener W., and MacKenzie C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 467 (1999) 517-524
20. de la Cruz Jr. P.O., Specht C.S., and McLean I.W. Lymphocytic infiltration in uveal malignant melanoma. Cancer 65 (1990) 112-115
21. Dick R., Murray B.P., Reid M.J., and Correia M.A. Structure-function relationships of rat hepatic tryptophan 2,3-dioxygenase: identification of the putative heme-ligating histidine residues. Arch. Biochem. Biophys. 392 (2001) 71-78
22. Egan K.M., Seddon J.M., Glynn R.J., Gragoudas E.S., and Albert D.M. Epidemiologic aspects of uveal melanoma. Surv. Ophthalmol. 32 (1988) 239-251
23. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., and Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196 (2002) 459-468
24. Gervois N., Labarriere N., Le Guiner S., Pandolfino M.C., Fonteneau J.F., Guilloux Y., Diez E., Dreno B., and Jotereau F. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin. Cancer Res. 6 (2000) 1459-1467
25. Goslings W.R., Blom D.J., de Waard-Siebinga I., van Beelen E., Claas F.H., Jager M.J., and Gorter A. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest. Ophthalmol. Vis. Sci. 37 (1996) 1884-1891
26. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., Pinedo H.M., and van den Eertwegh A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55 (2006) 451-458
27. Hainz U., Jurgens B., and Heitger A. The role of indoleamine 2,3-dioxygenase in transplantation. Transplant Int. 20 (2007) 118-127
28. Hayashi T., Beck L., Rossetto C., Gong X., Takikawa O., Takabayashi K., Broide D.H., Carson D.A., and Raz E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114 (2004) 270-279
29. Honig A., Rieger L., Kapp M., Sutterlin M., Dietl J., and Kammerer U. Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance. J. Reprod. Immunol. 61 (2004) 79-86
30. Ino K., Yoshida N., Kajiyama H., Shibata K., Yamamoto E., Kidokoro K., Takahashi N., Terauchi M., Nawa A., Nomura S., Nagasaka T., Takikawa O., and Kikkawa F. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 95 (2006) 1555-1561
31. Ishio T., Goto S., Tahara K., Tone S., Kawano K., and Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 19 (2004) 319-326
32. Jampel H.D., Roche N., Stark W.J., and Roberts A.B. Transforming growth factor-beta in human aqueous humor. Curr. Eye Res. 9 (1990) 963-969
33. Kudo Y., and Boyd C.A. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim. Biophys. Acta 1500 (2000) 119-124
34. Malina H.Z., and Martin X.D. Indoleamine 2,3-dioxygenase activity in the aqueous humor, iris/ciliary body, and retina of the bovine eye. Graefes Arch. Clin. Exp. Ophthalmol. 231 (1993) 482-486
35. Malina H.Z., and Martin X.D. Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye. Graefes Arch. Clin. Exp. Ophthalmol. 234 (1996) 457-462
36. Mellor A.L., Keskin D.B., Johnson T., Chandler P., and Munn D.H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 168 (2002) 3771-3776
37. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., and Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998) 1191-1193
38. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., and Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999) 1363-1372
39. Niederkorn J.Y. Immune privilege in the anterior chamber of the eye. Crit. Rev. Immunol. 22 (2002) 13-46
40. Niederkorn J.Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7 (2006) 354-359
41. Ohta K., Wiggert B., Taylor A.W., and Streilein J.W. Effects of experimental ocular inflammation on ocular immune privilege. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2010-2018
42. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., Gupta R., Lee L.Y., Kidd B.A., Robinson W.H., Sobel R.A., Selley M.L., and Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310 (2005) 850-855
43. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Sporn M.B., Burlington D.B., Lane H.C., and Fauci A.S. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136 (1986) 3916-3920
44. Sedlmayr P., Blaschitz A., Wintersteiger R., Semlitsch M., Hammer A., MacKenzie C.R., Walcher W., Reich O., Takikawa O., and Dohr G. Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta. Mol. Hum. Reprod. 8 (2002) 385-391
45. Singh A.D., Bergman L., and Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol. Clin. North Am. 18 (2006) 75-84
46. Staibano S., Mascolo M., Tranfa F., Salvatore G., Mignogna C., Bufo P., Nugnes L., Bonavolonta G., and De Rosa G. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?. Int. J. Immunopathol. Pharmacol. 19 (2006) 171-179
47. Sutmuller R.P., Schurmans L.R., van Duivenvoorde L.M., Tine J.A., van Der Voort E.I., Toes R.E., Melief C.J., Jager M.J., and Offringa R. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J. Immunol. 165 (2000) 7308-1735
48. Takikawa O., Habara-Ohkubo A., and Yoshida R. Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer. Adv. Exp. Med. Biol. 294 (1991) 437-444
49. Takikawa O., Littlejohn T., Jamie J.F., Walker M.J., and Truscott R.J. Regulation of indoleamine 2,3-dioxygenase, the first enzyme in UV filter biosynthesis in the human lens. Relevance for senile nuclear cataract. Adv. Exp. Med. Biol. 467 (1999) 241-245
50. Terness P., Bauer T.M., Rose L., Dufter C., Watzlik A., Simon H., and Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196 (2002) 447-457
51. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 269-274
52. Valmori D., Dutoit V., Ayyoub M., Rimoldi D., Guillaume P., Lienard D., Lejeune F., Cerottini J.C., Romero P., and Speiser D.E. Simultaneous CD8+T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3 (2003) 15-28
53. Verbik D.J., Murray T.G., Tran J.M., and Ksander B.R. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int. J. Cancer 73 (1997) 470-478
54. Weinlich G., Murr C., Richardsen L., Winkler C., and Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214 (2007) 8-14
55. Whelchel J.C., Farah S.E., McLean I.W., and Burnier M.N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 34 (1993) 2603-2606